

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558

Status	RECRUITING
Phase	Phase 2
Sponsor	AbbVie
Enrollment	240 participants

Key Eligibility Criteria

Inclusion (2)

- Autosomal Dominant Polycystic Kidney Disease (ADPKD) Class 1C, 1D, or 1E based on the Mayo Clinic Imaging Classification of ADPKD.
- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² and < 90 mL/min/1.73 m², using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening.

Exclusion (2)

- Current interventions to treat ADPKD such as non-approved medications or lifestyle modifications.
- Any exclusionary medical diseases, disorders, or conditions as described in the protocol.

Locations (75 total)

National Institute of Clinical Research - Garden Grove /ID# 271418, Garden Grove, California, United States
Valiance Clinical Research - Huntington Park /ID# 270634, Huntington Park, California, United States
Academic Medical Research Institute - Los Angeles /ID# 270502, Los Angeles, California, United States
... and 72 more locations